Clinical trial · Interventional
Aromatherapy Inhaler Use for HSCT Distress
Aromatherapy Inhaler Use for Hematopoietic Stem Cell Transplant Patient Distress
NCT05302583CI-TRIAL-00121569recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This randomized controlled trial will evaluate the feasibility and acceptability of an inhaled aromatherapy stick for patients during the acute inpatient phase after hematopoietic cell transplantation (HCT) . The study will also explore whether aromatherapy use is associated with short-term changes in patient-reported cancer-related distress and coping self-efficacy.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Aromatherapy | — | UNRESOLVED | — |
| Cancer Coping | — | UNRESOLVED | — |
| Cancer Distress | — | UNRESOLVED | — |
| Hematopoetic Stem Cell Transplant | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Aromatherapy Stick | Other | — | UNRESOLVED |
| Standard of Care | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Usual Care
- description
- Participants receive standard supportive care during hospitalization. No aromatherapy stick is provided.
- interventionNames
- Other: Standard of Care
- type
- EXPERIMENTAL
- label
- Aromatherapy + Usual Care
- description
- Participants receive standard supportive care plus aromatherapy inhaler education and an aromatherapy stick for self-administered inhalation. Aromatherapy use occurs on the assigned Inhaler Use Day (targeted for Transplant Day +1, +2, or +3). Use is tracked with an inhaler use log. The aromatherapy "dose" is standardized by a maximum total exposure time (up to 2 hours total), while allowing participants to choose how to distribute use.
- interventionNames
- Other: Aromatherapy Stick
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Autologous and Allogeneic patients admitted to E1 for planned HSCT * Patients with hematologic malignancies requiring HSCT * No allergies to lavender or peppermint essential oils * Must have received chemotherapy during preparative regimen (single or multi-agent regimen) * Adult patient over 18 years of age * Able to speak, read, and comprehend English * Willing and capable of providing informed consent Exclusion Criteria: * Patients admitted for Chimeric Antigen Receptor T cell (CART) infusion * Patients receiving a transplant for a germ cell tumor diagnosis * Unexpected/unplanned admission (e.g., neutropenic fever, confusion, clinical deterioration) * Immune effector cell-associated neurotoxicity syndrome (ICANS) grade 1 through 4 * History of scleroderma * History of atrial fibrillation * Known history of G6PD deficiency * Allergic to lavender or peppermint essential oils * Pediatric patient 18 years of age or less * Unable to speak, read, and comprehend English * Unwilling or incapable of providing informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.